crestor
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.94 | $58.35 (0%) | 🛒 Add to cart |
| 60 | $1.53 | $116.70 $91.55 (22%) | 🛒 Add to cart |
| 90 | $1.37 | $175.05 $123.74 (29%) | 🛒 Add to cart |
| 120 | $1.31 | $233.40 $156.94 (33%) | 🛒 Add to cart |
| 180 | $1.22 | $350.10 $220.32 (37%) | 🛒 Add to cart |
| 270 | $1.18
Best per pill | $525.15 $319.92 (39%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.98 | $89.54 (0%) | 🛒 Add to cart |
| 60 | $2.21 | $179.07 $132.80 (26%) | 🛒 Add to cart |
| 90 | $1.97 | $268.61 $177.06 (34%) | 🛒 Add to cart |
| 120 | $1.84 | $358.15 $220.32 (38%) | 🛒 Add to cart |
| 180 | $1.71 | $537.22 $307.84 (43%) | 🛒 Add to cart |
| 270 | $1.62
Best per pill | $805.83 $437.62 (46%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.84 | $50.30 (0%) | 🛒 Add to cart |
| 90 | $0.75 | $75.45 $67.40 (11%) | 🛒 Add to cart |
| 120 | $0.71 | $100.60 $85.51 (15%) | 🛒 Add to cart |
| 180 | $0.67 | $150.90 $120.72 (20%) | 🛒 Add to cart |
| 270 | $0.64 | $226.36 $172.03 (24%) | 🛒 Add to cart |
| 360 | $0.63
Best per pill | $301.81 $226.36 (25%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Crestor, known generically as rosuvastatin calcium, is a synthetic lipid-lowering agent belonging to the statin class of medications. Marketed globally by AstraZeneca, this HMG-CoA reductase inhibitor represents one of the most potent prescription medications available for managing dyslipidemia. Unlike many dietary supplements that make vague health claims, Crestor operates through a well-defined biochemical pathway with extensive clinical validation spanning decades of research and real-world application.
Crestor: Potent LDL-C Reduction for Cardiovascular Risk Management - Evidence-Based Review
1. Introduction: What is Crestor? Its Role in Modern Medicine
Crestor contains the active pharmaceutical ingredient rosuvastatin calcium in various strengths (5mg, 10mg, 20mg, 40mg). As a prescription medication rather than a dietary supplement, Crestor undergoes rigorous FDA oversight and requires proper medical supervision. The primary indication for Crestor centers on atherosclerotic cardiovascular disease (ASCVD) risk reduction through comprehensive lipid management.
What makes Crestor particularly significant in clinical practice is its position as one of the most potent statins available, with milligram-for-milligram LDL-cholesterol lowering capability exceeding that of earlier generation statins. This potency profile makes Crestor especially valuable for patients requiring aggressive lipid control, including those with familial hypercholesterolemia or established cardiovascular disease.
2. Key Components and Bioavailability Crestor
The pharmaceutical composition of Crestor revolves around rosuvastatin calcium as the sole active ingredient. The molecular structure features a polar methane-sulfonamide group that contributes to its distinctive pharmacokinetic profile, particularly its hydrophilic properties and limited penetration into non-hepatic tissues.
Bioavailability of Crestor averages approximately 20%, with peak plasma concentrations occurring 3-5 hours post-administration. Unlike lipophilic statins, rosuvastatin’s hydrophilic nature reduces passive diffusion into extrahepatic tissues, potentially contributing to its favorable muscle safety profile. The medication undergoes minimal metabolism via cytochrome P450 2C9, with approximately 90% excreted unchanged in feces—this reduced metabolic burden creates fewer drug interaction concerns compared to statins heavily dependent on CYP450 pathways.
The tablet formulation includes standard pharmaceutical excipients: microcrystalline cellulose, lactose monohydrate, tribasic calcium phosphate, crospovidone, magnesium stearate, hyprolose, triacetin, titanium dioxide, yellow ferric oxide, and red ferric oxide. The absence of complex delivery systems or bioavailability enhancers reflects the inherent favorable absorption characteristics of the molecule itself.
3. Mechanism of Action Crestor: Scientific Substantiation
Crestor operates through competitive inhibition of HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, and rosuvastatin’s structural similarity to the natural HMG-CoA substrate allows it to bind with approximately 100-fold greater affinity than the endogenous compound.
The primary site of action is hepatic tissue, where inhibition of cholesterol synthesis creates a cascade of effects: reduced intracellular cholesterol concentrations trigger increased expression of LDL receptors on hepatocyte surfaces. These upregulated receptors enhance clearance of LDL and LDL precursors from circulation, resulting in the substantial reductions in LDL-C observed clinically.
Beyond this classical mechanism, research suggests pleiotropic effects including improved endothelial function, enhanced plaque stability, reduced oxidative stress, and anti-inflammatory properties—though the clinical significance of these additional mechanisms remains debated within the cardiology community.
4. Indications for Use: What is Crestor Effective For?
Crestor for Primary Hyperlipidemia and Mixed Dyslipidemia
The foundational indication for Crestor management includes patients with elevated LDL-C, non-HDL-C, and ApoB levels. Clinical trials consistently demonstrate 45-63% reductions in LDL-C depending on dosage, with corresponding improvements in other atherogenic lipid parameters.
Crestor for Primary Prevention of Cardiovascular Events
The JUPITER trial fundamentally expanded Crestor’s role by demonstrating significant cardiovascular risk reduction in apparently healthy individuals with elevated high-sensitivity C-reactive protein (hsCRP) but normal LDL-C levels. This landmark study showed 44% relative risk reduction in major cardiovascular events among patients treated with rosuvastatin 20mg daily versus placebo.
Crestor for Secondary Prevention in Established Cardiovascular Disease
For patients with documented ASCVD, Crestor provides robust protection against recurrent events. The CORONA and GISSI-HF trials specifically evaluated rosuvastatin in heart failure populations, while numerous real-world studies confirm its effectiveness in post-MI, post-revascularization, and stroke prevention contexts.
Crestor for Pediatric Patients with Heterozygous Familial Hypercholesterolemia
FDA approval extends to children aged 8-17 with HeFH, with studies showing similar lipid-lowering efficacy and safety profile to adult populations. Dosing must be carefully individualized based on therapeutic response and tolerability.
Crestor for Hypertriglyceridemia
Though primarily recognized for LDL-C reduction, Crestor demonstrates moderate efficacy in triglyceride management, typically achieving 20-35% reductions from baseline levels.
5. Instructions for Use: Dosage and Course of Administration
Crestor dosing follows a standardized approach with necessary individualization based on patient characteristics, treatment goals, and tolerability:
| Indication | Starting Dose | Maximum Dose | Administration Timing |
|---|---|---|---|
| Primary prevention | 10-20mg daily | 40mg daily | Once daily, with or without food |
| Secondary prevention | 20mg daily | 40mg daily | Consistent timing recommended |
| Severe hypercholesterolemia | 20mg daily | 40mg daily | May take 2-4 weeks for full effect |
| Asian patients | 5mg daily | 20mg daily | Reduced dosing due to pharmacokinetic differences |
Dose adjustments may be necessary for patients with renal impairment, particularly those with CrCl <30 mL/min, where initiation at 5mg daily is recommended. Regular monitoring of liver enzymes and lipid parameters should occur at 4-12 week intervals initially, then periodically thereafter.
The course of administration is typically long-term, as cardiovascular risk reduction benefits accumulate over time and discontinuation generally leads to return to pretreatment lipid levels within 2-4 weeks.
6. Contraindications and Drug Interactions Crestor
Absolute contraindications for Crestor include active liver disease or unexplained persistent elevations in hepatic transaminases, pregnancy, and breastfeeding. Relative contraindications encompass concomitant use with cyclosporine, significant alcohol abuse, and history of statin intolerance.
Drug interactions require careful consideration:
- Cyclosporine: Concomitant use increases rosuvastatin exposure up to 7-fold—contraindicated
- Gemfibrozil: Avoid combination due to increased risk of myopathy
- Antacids: Administration simultaneously with aluminum/magnesium hydroxide reduces rosuvastatin absorption—separate by at least 2 hours
- Warfarin: Monitor INR closely as rosuvastatin may potentiate effect
- Protease inhibitors: Certain combinations may increase statin exposure
The most concerning adverse effects involve musculoskeletal system, with myalgias occurring in 5-10% of patients and more serious rhabdomyolysis occurring rarely (<0.1%). Hepatic transaminase elevations >3x ULN occur in 0.5-2.0% of patients, typically asymptomatic and reversible with discontinuation.
7. Clinical Studies and Evidence Base Crestor
The evidence foundation for Crestor spans numerous landmark trials across diverse patient populations:
JUPITER Trial (2008): 17,802 apparently healthy men and women with LDL-C <130 mg/dL but hsCRP ≥2.0 mg/L received rosuvastatin 20mg or placebo. The trial was stopped early after median 1.9 years due to 44% reduction in primary endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes).
ASTEROID Trial (2006): IVUS examination demonstrated statistically significant regression of coronary atherosclerosis following 24 months of rosuvastatin 40mg daily treatment—the first study to show actual plaque regression with statin monotherapy.
CORONA Trial (2007): Evaluated rosuvastatin in older heart failure patients, showing significant reduction in cardiovascular hospitalizations though no mortality benefit in this advanced heart failure population.
Real-world evidence from registries and observational studies consistently confirms the randomized trial findings, with some data suggesting even greater absolute risk reduction in clinical practice where patients often have higher baseline risk than trial participants.
8. Comparing Crestor with Similar Products and Choosing a Quality Product
When comparing Crestor to other statins, several distinguishing characteristics emerge:
| Statin | Potency (mg for mg) | Metabolism | Food Effect | Generic Availability |
|---|---|---|---|---|
| Rosuvastatin (Crestor) | Highest | Minimal CYP450 | None | Yes (since 2016) |
| Atorvastatin (Lipitor) | High | CYP3A4 | Moderate | Yes |
| Simvastatin (Zocor) | Moderate | CYP3A4 | Significant | Yes |
| Pravastatin (Pravachol) | Low | Sulfation | Significant | Yes |
The transition to generic availability in 2016 substantially improved cost-effectiveness, though some clinicians still prefer the branded formulation for certain patients based on individual response characteristics. Bioequivalence studies confirm therapeutic equivalence between brand and generic rosuvastatin.
Selection considerations should include potency requirements, drug interaction profile, patient comorbidities, and cost factors. For patients requiring >50% LDL-C reduction, rosuvastatin often represents the most straightforward monotherapy option.
9. Frequently Asked Questions (FAQ) about Crestor
What is the recommended course of Crestor to achieve results?
Therapeutic lipid lowering typically occurs within 2-4 weeks of initiation, but cardiovascular risk reduction represents a long-term benefit requiring ongoing treatment. Discontinuation generally results in return to baseline lipid levels within several weeks.
Can Crestor be combined with other cholesterol medications?
Combination therapy may be appropriate for patients not achieving goals with statin monotherapy. Ezetimibe represents the most evidence-based combination, while fenofibrate may be considered for mixed dyslipidemia with precautions regarding myopathy risk.
What monitoring is required during Crestor treatment?
Baseline and periodic lipid panels, liver function tests, and clinical assessment for muscle symptoms constitute standard monitoring. Some guidelines have moved toward less frequent LFT monitoring in stable patients.
Are there dietary restrictions with Crestor?
No specific dietary restrictions, though National Cholesterol Education Program therapeutic lifestyle changes should accompany pharmacotherapy for comprehensive management.
How does Crestor affect blood sugar?
Statins modestly increase hemoglobin A1c and diabetes incidence, with analysis suggesting this effect is likely a class effect rather than specific to rosuvastatin.
10. Conclusion: Validity of Crestor Use in Clinical Practice
Crestor maintains a well-established position in the cardiovascular prevention arsenal, supported by robust efficacy data and generally favorable tolerability profile. The risk-benefit assessment clearly favors appropriate use in indicated populations, with the diabetes risk and myopathy concerns generally outweighed by substantial cardiovascular event reduction.
The availability of generic formulations has improved accessibility while maintaining the proven therapeutic benefits. Ongoing research continues to refine our understanding of optimal patient selection, particularly in primary prevention populations where individualized risk assessment remains crucial.
I remember when we first started using rosuvastatin back in 2003—our cardiology group was divided between the established atorvastatin loyalists and those willing to try this new supposedly more potent option. Dr. Williamson, our senior partner, was skeptical it would offer anything beyond marginal improvements, while the younger attendings were eager to leverage the enhanced potency.
The turning point came with Mrs. Gable, a 58-year-old with familial hypercholesterolemia who’d failed to reach LDL goals on maximum atorvastatin. Her baseline LDL was 189 despite 80mg daily, and she was developing mild transaminase elevations. We switched her to rosuvastatin 20mg and within 4 weeks her LDL dropped to 78—the lowest it had been in the 15 years we’d been treating her. What surprised me wasn’t just the number, but how her adherence improved because she finally saw dramatic results.
Then there was Mr. Davison, the 72-year-old with recurrent MIs despite what should have been adequate lipid control on simvastatin. His inflammatory markers were persistently elevated, and we were struggling to get his residual risk under control. After switching to rosuvastatin, not only did his lipids improve further, but his hsCRP normalized for the first time in years. He’s now eight years out from his last cardiovascular event.
The learning curve wasn’t without missteps though. We initially underestimated the potency in Asian patients until we encountered several cases of unexpectedly high drug levels and muscle toxicity at what we considered moderate doses. That forced us to develop specific protocols for our diverse patient population.
The real testament came from longitudinal follow-up of our statin-treated patients. When I recently reviewed outcomes for the 327 patients we’ve maintained on rosuvastatin for over 5 years, the cardiovascular event rates were substantially lower than what we’d historically seen with other statins, particularly in those with high baseline inflammatory markers. Mrs. Gable still comes in quarterly, now 76 years old, and never fails to mention how this medication literally changed her life trajectory. “I’m watching my grandchildren grow up because of this little pill,” she told me last visit—a reminder that behind the pharmacokinetics and clinical endpoints are real human stories.